WVE

WVE

USD

Wave Life Sciences Ltd. Ordinary Shares

$8.010+0.000 (0.000%)

Prix en Temps Réel

Healthcare
Biotechnologie
Singapour

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$8.010

Haut

$8.270

Bas

$7.950

Volume

1.95M

Fondamentaux de l'Entreprise

Capitalisation Boursière

1.3B

Industrie

Biotechnologie

Pays

Singapore

Statistiques de Trading

Volume Moyen

2.52M

Bourse

NGM

Devise

USD

Intervalle sur 52 Semaines

Bas $5.28Actuel $8.010Haut $16.74

Actualités Connexes

GlobeNewswire

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle mass with once or

Voir plus
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
GlobeNewswire

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025

CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will

Voir plus
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
GlobeNewswire

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

This press release corrects and replaces the company's press release issued today, 10/29, at 4:15 p.m. ET in order to correct a typographical error in the first sub-bullet under "WVE-007 (GalNAc-siRNA)" – "Next steps."

Voir plus
Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
GlobeNewswire

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is generally safe and well

Voir plus
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
Analyst Upgrades

Clear Street Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $22

Clear Street analyst Bill Maughan initiates coverage on WAVE Life Sciences with a Buy rating and announces Price Target of $22.

Voir plus
Clear Street Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $22

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.